The focus going forward is to move the operations to digital pathology so we can both use and develop new AI tools to improve efficiency and quality.

Aug 7, 2026 / receipt

We're executing against our strategic initiatives to drive AI and digital solutions across our laboratory services business

Aug 7, 2026 / receipt

we are managing the final phase of the transition of our billing and revenue cycle management system.

Aug 7, 2026 / receipt

The increase in consolidated selling and marketing expenses was due to increase of $4.7 million resulting from assets and the business acquired in the Bako Acquisition, $2.2 million in personnel costs due to increased headcount, and $1.4 million in software and software licensing, partially offset by decreases of $1.9 million in advertising and marketing expenses.

filing / Jul 30, 2026 / receipt

This was driven by the lower collection rate and higher fixed costs, reducing operating leverage primarily resulting from processing and collections delays in connection with the final phase of the implementation of our new billing and revenue cycle management system.

filing / Jul 30, 2026 / receipt

The Company is a lessee to various non-cancelable operating leases with varying terms through March 2034 , primarily for laboratory and office space and equipment.

filing / Jul 30, 2026 / receipt

The increase in consolidated selling and marketing expenses was due to increases of $2.4 million in personnel expenses, $1.1 million in software licensing, $0.2 million in travel expenses, $0.1 million in trade show expenses, and $0.1 million in supply and material expenses, partially offset by a decrease of $0.1 million in consulting expenses.

filing / May 1, 2026 / receipt

The increase was primarily due to increases of $1.8 million in personnel expenses due to increased headcount, $1.5 million in shipping and handling expenses, $0.7 million in reagent and supply costs, $0.5 million in depreciation expense, and $0.5 million in consulting costs, and partially offset by a decrease of $0.5 million in

filing / May 1, 2026 / receipt

This was driven by the decreased revenue, for the reasons described above, and increased headcount. Research and Development Three Months Ended March 31, 2026 2025 $ Change % Change (in thousands, except percentages) Research and development Laboratory services $ 8,493 $ 7,082 $ 1,411 20 % Therapeutic development 5,683 5,313 370 7 % Total research and development $

filing / May 1, 2026 / receipt

The unaudited pro forma financial information does not reflect any cost savings, operating synergies, or revenue enhancements that the combined company may achieve as a result of the acquisition, the costs to integrate the operations of Fulgent and Bako, or the costs necessary to achieve those cost savings, operating synergies, and revenue enhancements.

filing / May 1, 2026 / receipt

Transaction bonus and acquisition-related severance costs - A transaction bonus of $ 3.6 million paid by Bako and a separation payment of $ 0.4 million paid to a former officer of Bako by the combined entity have been excluded from pro forma net loss f or the three months ended March 31, 2026, as those obligations arose directly from the change-in-control provisions of Bako’s pre-existing employment agreements and is

filing / May 1, 2026 / receipt

The Company is a lessee to various non-cancelable operating leases with varying terms through March 2034 , primarily for laboratory and office space and equipment.

filing / May 1, 2026 / receipt

Aircraft N369FG, registered to FULGENT GENETICS INC, landed at KBZN (Bozeman Yellowstone International Airport) on 2026-08-21. KBZN is 1.2 miles from the headquarters of Bridger Aerospace Group Holdings Inc. in BELGRADE, MT.

company_statement / Aug 21, 2026 / receipt

Aircraft N369FG, registered to FULGENT GENETICS INC, landed at KBZN (Bozeman Yellowstone International Airport) on 2026-08-21. KBZN is 1.2 miles from the headquarters of Xtant Medical Holdings Inc. in Belgrade, MT.

company_statement / Aug 21, 2026 / receipt

Aircraft N369FG, registered to FULGENT GENETICS INC, landed at KBZN (Bozeman Yellowstone International Airport) on 2026-08-21. KBZN is 8.2 miles from the headquarters of Destra Multi-Alternative Fund in Bozeman, MT.

company_statement / Aug 21, 2026 / receipt